PKU HealthCare Corp.,Ltd. engages in the research, development, production, and sale of chemical pharmaceutical preparations, pharmaceutical distribution, and medical services in China. The company offers anti-infectives, analgesics, psychotropic drugs, digestive system drugs, and cardiovascular drugs; procurement and pharmacy outsourcing; and cancer screening, health management, and treatment services related to healthcare management and care delivery, as well as involved in distribution, retail, and hospital sales of pharmaceuticals, medical devices, and consumables. It also provides ceftriaxone sodium, meropenem, and cefminox sodium for injection; moxifloxacin hydrochloride injection; clindamycin palmitate hydrochloride granules; naphazoline capsules; celecoxib capsules; dextroketoneprofen tablets and capsules; buspirone hydrochloride tablets; and olanzapine tablets. The company was formerly known as PUK International Hospital Group Southwest Synthetic Pharmaceutical Corp., Ltd. and changed its name to PKU HealthCare Corp., Ltd. in November 2013. PKU HealthCare Corp.,Ltd. was founded in 1993 and is headquartered in Chongqing, China.